We discuss Allergan’s (AGN) creative legal approach to protecting its IP for its RESTASIS drug by transferring all its patents to the Saint Regis Mohawk Tribe. Read the full discussion on our SeekingAlpha Marketplace page.
This author has yet to write their bio.Meanwhile lets just say that we are proud SM contributed a whooping 83 entries.
Entries by SM
Our daily analysis of a stock with a major event/upside: Nabriva (NBRV) stock doubled on 200x normal volume (Vol / Avg. 17.49M/74,701.00) on the back of positive results from one of two pivotal phase trials evaluating intravenous to oral lefamulin in patients with community-acquired bacterial pneumonia (CABP). Read full post in our daily pharma scoop […]
Acadia (ACAD) Nuplazid looks at market potential of $10bn for PDP and $50bn for ADP. Read the complete scoop in our Daily Pharma Scoop at SeekingAlpha Marketplace.
Neos Therapeutics (NEOS) saw a sell-off on Friday despite getting approval for its Adzenys ER treatment for ADHD that same day. Read our take on the news, in our Daily Pharma Scoop at SeekingAlpha Marketplace.
Tesaro’s (TSRO) Zejula, approved by the FDA in March, received a positive CHMP opinion in EU. We have Marketplace research on TSRO available.
Array BioPharma (ARRY) has a public offering of 20,930,232 shares of common stock at $10.75 per share. Stock is currently at $10.82. ... overall we were neutral. Read why, in our Daily Pharma Scoop at SeekingAlpha Marketplace.
Radius Health, Inc. (RDUS) insider purchases: 10% +$5,017,975 Pres, CEO +$199,608 CFO +$98,503 Check out all pharma insider purchases in our SeekingAlpha Marketplace Daily Pharma Scoop.
Insider sales at Fibrogen Inc. Chief Medical Officer -$145,401 Dir -$1,298,000 CEO -$1,996,274 Check out all pharma insider sales in our SeekingAlpha Marketplace Daily Pharma Scoop.
Jefferies Group Upgrades NewLink Genetics Corporation (NLNK) Hold -> Buy raising target $7.00 -> $26.00. Robert W. Baird also Upgrades NLNK Neutral -> Outperform raising target $8.00 -> $22.00. Cantor Fitzgerald Reiterates Overweight with target of $26.00. Check out more ratings and analysis on our SeekingAlpha Marketplace Daily Pharma Scoop.
Morgan Stanley Downgrades Mallinckrodt PLC (MNK) from Overweight -> Equal Weight reducing target $65.00 -> $40.00, while Piper Jaffray, Stifel Nicolaus, Mizuho, Cantor Fitzgerald reiterate BUY with targets ranging from $52 to $85. Get in-depth analysis in our Daily Pharma Scoop at SeekingAlpha Marketplace.